Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma is a research paper published in Leukemia (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
MEXT | Japan Society for the Promotion of Science
Grant: JP21H02775
MEXT | Japan Society for the Promotion of Science
Grant: 23K15314
Takeda Pharmaceutical Company
Grant: NA
U.S. Department of Health & Human Services | National Institutes of Health
Grant: R01 CA259188
U.S. Department of Health & Human Services | National Institutes of Health
Grant: R01 CA251674
American Cancer Society
Grant: RSG-23-722314
National Institutes of Health
Grant: 5R01CA259188-03
Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy
National Institutes of Health
Grant: 5R01CA251674-04
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma
FWCI
0.30
Citation Percentile
0.6%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals